Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Phillip Chappell

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Journal of the American Academy of Child and Adolescent Psychiatry|May 25, 2006
Electrocardiographic changes with ziprasidoneAntony Loebel, Jeffrey Miceli, Phillip Chappell, et al.
The American Journal of Psychiatry|June 12, 2012
Initial validity and reliability data on the Columbia-Suicide Severity Rating ScalePhillip Chappell, Douglas E Feltner, Clare Makumi, et al.
Brain and Cognition|September 24, 2004
Voice acoustical measurement of the severity of major depressionMichael Cannizzaro, Brian Harel, Nicole Reilly, et al.
Journal of Child and Adolescent Psychopharmacology|January 23, 2020
Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity DisorderSharon Wigal, Phillip Chappell, Donna Palumbo, et al.
Journal of Child and Adolescent Psychopharmacology|October 25, 2022
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)Sarah Atkinson, Mary Bachinsky, Yaron Raiter, et al.
Journal of Psychiatric Practice|March 25, 2011
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorderOnur N Karayal, Paul Glue, Mary Bachinsky, et al.
Journal of Child and Adolescent Psychopharmacology|April 8, 2022
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication StudyRobert L Findling, Sarah Atkinson, Mary Bachinsky, et al.
Journal of Child and Adolescent Psychopharmacology|July 21, 2021
Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed SertralineFrancesca Kolitsopoulos, Sara Ramaker, Scott Compton, et al.
Paediatric Anaesthesia|February 16, 2024
A randomized, double-blind, dose-controlled study of the use of dexmedetomidine alone for procedural sedation of children and adolescents undergoing MRI scansUmar Khan, Gregory B Hammer, Cassandra Duncan-Azadi, et al.
Journal of Child and Adolescent Psychopharmacology|February 17, 2023
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)Francesca Kolitsopoulos, Sara Ramaker, Scott N Compton, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Journal of the American Academy of Child and Adolescent Psychiatry|May 25, 2006
Electrocardiographic changes with ziprasidoneAntony Loebel, Jeffrey Miceli, Phillip Chappell, et al.
The American Journal of Psychiatry|June 12, 2012
Initial validity and reliability data on the Columbia-Suicide Severity Rating ScalePhillip Chappell, Douglas E Feltner, Clare Makumi, et al.
Brain and Cognition|September 24, 2004
Voice acoustical measurement of the severity of major depressionMichael Cannizzaro, Brian Harel, Nicole Reilly, et al.
Journal of Child and Adolescent Psychopharmacology|January 23, 2020
Diagnosis and Treatment Options for Preschoolers with Attention-Deficit/Hyperactivity DisorderSharon Wigal, Phillip Chappell, Donna Palumbo, et al.
Journal of Child and Adolescent Psychopharmacology|October 25, 2022
26-Week Open-Label Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Most Recent Episode Manic)Sarah Atkinson, Mary Bachinsky, Yaron Raiter, et al.
Journal of Psychiatric Practice|March 25, 2011
Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorderOnur N Karayal, Paul Glue, Mary Bachinsky, et al.
Journal of Child and Adolescent Psychopharmacology|April 8, 2022
Efficacy, Safety, and Tolerability of Flexibly Dosed Ziprasidone in Children and Adolescents with Mania in Bipolar I Disorder: A Randomized Placebo-Controlled Replication StudyRobert L Findling, Sarah Atkinson, Mary Bachinsky, et al.
Journal of Child and Adolescent Psychopharmacology|July 21, 2021
Sertraline Pediatric Registry for the Evaluation of Safety: Design and Clinical Characteristics of Pediatric Patients Prescribed SertralineFrancesca Kolitsopoulos, Sara Ramaker, Scott Compton, et al.
Paediatric Anaesthesia|February 16, 2024
A randomized, double-blind, dose-controlled study of the use of dexmedetomidine alone for procedural sedation of children and adolescents undergoing MRI scansUmar Khan, Gregory B Hammer, Cassandra Duncan-Azadi, et al.
Journal of Child and Adolescent Psychopharmacology|February 17, 2023
Effects of Long-Term Sertraline Use on Pediatric Growth and Development: The Sertraline Pediatric Registry for The Evaluation of Safety (SPRITES)Francesca Kolitsopoulos, Sara Ramaker, Scott N Compton, et al.
Pageof 2